Search results
Results from the WOW.Com Content Network
If a drug can inhibit telomerase in cancer cells, the telomeres of successive generations will progressively shorten, limiting tumor growth. [56] Telomerase is a good biomarker for cancer detection because most human cancer cells express high levels of it. Telomerase activity can be identified by its catalytic protein domain .
Therefore, over-expression of hTERT, which is akin to increasing telomerase activities, may create adult stem cells with a larger capacity for differentiation and hence, a larger capacity for treatment. Increasing the telomerase activities in stem cells gives different effects depending on the intrinsic nature of the different types of stem ...
Two concerns with applying telomerase inhibitors in cancer treatment are that effective treatment requires continuous, long-term drug application and that off-target effects are common. [30] For example, the telomerase inhibitor imetelstat, first proposed in 2003, [31] [32] has been held up in clinical trials due to hematological toxicity. [30]
Dogs with this kind of cancer that have surgery usually only survive 3 to 18 months, depending on how advanced the cancer is when found (1). Squamous cell carcinoma: This is a good possibility ...
Telomerase RNA component, also known as TR, TER or TERC, is an ncRNA found in eukaryotes that is a component of telomerase, the enzyme used to extend telomeres. [ 3 ] [ 4 ] TERC serves as a template for telomere replication ( reverse transcription ) by telomerase.
TERRA is an evolutionarily conserved long-non-coding RNA found in many nucleus-containing eukaryotic cells such as chicken (Gallus gallus domesticus), [1] humans (Homo sapiens), budding yeast (Schizosaccharomyces cerevisiae), fission yeast (Schizosaccharomyces pombe), mice (Mus musculus), zebrafish (Danio rerio), and various plants (Arabidopsis thaliana, et cetera).
For most substances presented, the optimal levels are the ones normally found in the population as well. More specifically, optimal levels are generally close to a central tendency of the values found in the population. However, usual and optimal levels may differ substantially, most notably among vitamins and blood lipids, so these tables give ...
Since 2009, two tyrosine kinase inhibitors - masitinib (trade name Masivet) and toceranib (trade name Palladia) - have been approved for the treatment of mastocytomas in dogs in the EU. [17] [37] [38] Masitinib is approved for the treatment of unresectable grade 2 and 3 (or high-grade) mastocytomas with c-KIT mutation.